iotaSciences Launches New isoPick™ Single-Cell Picker to Further Expand Handling Solutions for Efficient Cell Biology & Gene Therapy Applications
First isoPick™ showcases at upcoming ELRIG CRISPR IN DRUG DISCOVERY 2023 event in Oxford (UK) and SLAS 2023 meeting in San Diego (USA).
February 7, 2023
by PharmaSources
Gene genies: Oxford Biomedica and Homology Medicines create AAV business
Leading gene and cell therapy group, Oxford Biomedica, and Homology Medicines, have announced that the companies will establish...
January 28, 2022
by pharmatimes
Schreiner MediPharm Develops Freeze-Lock Cryo Label
Withstands the sub-zero storage and transport temperatures needed for many cell and gene therapy medications or clinical trials.
January 27, 2022
by contractpharma
Sharp Expands Gene Therapy Packaging Capabilities
Invests in new gene therapy packaging and distribution capacity at EU Heerenveen facility.
January 26, 2022
by contractpharma
Ori Biotech Expands Cell and Gene Therapy Manufacturing Capabilities
Raises over $100 million in Series B funding to launch innovative cell and gene therapy manufacturing platform.
January 24, 2022
by contractpharma
Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy
Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application...
January 20, 2022
by prnasia
CBM and Penn Strike $100M Cell & Gene Therapy Deal
Penn’s innovation in process science combines with CBM manufacturing capability..
January 20, 2022
by contractpharma
Novartis to acquire UK’s Gyroscope Therapeutics for up to $1.5bn
Novartis has signed a definitive agreement for the acquisition of all the outstanding shares of UK’s ocular gene therapy firm Gyroscope Therapeutics, in a deal worth up to $1.5bn.
December 24, 2021
by Pharmaceutical-Technology
EMA Grants Accelerated Assessment for CSL Behring's Hemophilia B Gene Therapy
CSL Behring announced that the European Medicines Agency (EMA) has granted its approval for an accelerated assessment request for etranacogene dezaparvovec Marketing Authorization Application (MAA). Etranacogene dezaparvovec is an investigational gene...
December 16, 2021
by AmericanPharmaceuticalReview
Experimental gene therapy reverses sickle cell disease for three years
A study of an investigational gene therapy for sickle cell disease at Columbia University Irving Medical Centre, US, has found that a single dose restored blood cells to their normal shape...
December 15, 2021
by EuropeanPharmaceuticalReview
Could Gene Therapy Help Cure Sickle Cell Disease?
A gene therapy that could provide a permanent cure for sickle cell disease continues to show success through a third wave of patients, researchers report.
December 14, 2021
by Drugs
Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies
Neurophth Therapeutics Ltd., ("Neurophth"), a fully integrated genomic medicines company dedicated on seeking to improve lives through the curative potential of gene therapies...
November 24, 2021
by prnasia